Johnson & Johnson (NYSE:JNJ) is Illinois Municipal Retirement Fund's 7th Largest Position

Illinois Municipal Retirement Fund boosted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.5% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 385,653 shares of the company's stock after buying an additional 16,763 shares during the quarter. Johnson & Johnson makes up approximately 0.9% of Illinois Municipal Retirement Fund's portfolio, making the stock its 7th largest holding. Illinois Municipal Retirement Fund's holdings in Johnson & Johnson were worth $63,957,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Johnson & Johnson by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock worth $33,666,460,000 after acquiring an additional 1,772,706 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Johnson & Johnson by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock worth $8,321,881,000 after purchasing an additional 1,561,036 shares in the last quarter. Northern Trust Corp raised its position in shares of Johnson & Johnson by 12.3% in the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock valued at $4,456,201,000 after purchasing an additional 3,363,235 shares during the period. Norges Bank purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at approximately $4,390,037,000. Finally, Wellington Management Group LLP boosted its holdings in Johnson & Johnson by 1.8% in the 4th quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company's stock worth $3,522,447,000 after buying an additional 431,205 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on JNJ. Barclays lowered their target price on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Bank of America cut their target price on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Wall Street Zen raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 21st. Finally, Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Price Performance

Shares of JNJ stock traded up $0.17 during trading hours on Monday, hitting $152.58. 9,000,581 shares of the company's stock were exchanged, compared to its average volume of 8,022,908. The company has a market capitalization of $367.12 billion, a PE ratio of 16.97, a PEG ratio of 2.31 and a beta of 0.42. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The business's 50 day simple moving average is $153.75 and its 200-day simple moving average is $153.81.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.41%. The ex-dividend date of this dividend was Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.